IMCR News and Press, Immunocore Holdings plc From 08/10/22

Immunocore Reports Second Quarter 2022 Financial Results and Provides Business Update KIMMTRAK® ( tebentafusp ) now approved in over 30 countries with commercial launches underway in U.S. and Germany, and paid access in France Net KIMMTRAK / tebentafusp ...

Immunocore to Report Second Quarter 2022 Earnings and Host Call on August 10, 2022 (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 3 August 2022) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a comme...

Immunocore announces upcoming oral presentation of initial Phase 1 data of ImmTAC ® candidate IMC-F106C targeting PRAME at European Society for Medical Oncology (ESMO) Congress 2022 Oral presentation in proffered paper s...

100% technical buy signals. 13 new highs and up 38.33% in the last month. Price targets as high as $78.95. The Chart of the Day belongs to the healthcare biotech company Immunocore ( IMCR ). I found the stock by sorting Barchart's Top Stocks to Own list first by ...

Immunocore ( NASDAQ: IMCR ) agreed to sell 3.7M shares, consisting of 2M ADSs with each ADS representing one ordinary share, and 1.7M non-voting ordinary shares, to certain institutional accredited investors through a private investment in public equity financing at a pri...

P RESS RELEASE Immunocore A nnounces $ 140 Million Private Placement Financing (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 18 July 2022) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the &#...

It's been an ugly year in the stock market in 2022, and most investors are deep in the red. But there's always a winner somewhere. Right now healthcare is seeing a lot of bright spots. For instance, Immunocore (NASDAQ: IMCR) investors just had a U.S. Food and Drug Administration...

P RESS RELEASE Immunocore announces dosing of first patient with ImmTAV ® bispecific for HIV IMC-M113V , T cell receptor bispecific , target s an HIV Gag antigen Single Ascending Dose portion of Phase 1 study to eval...

Baker Brothers’ 13F portfolio value decreased from $20.55B to $17.40B this quarter. Horizon Therapeutics was increased while decreasing Legend Biotech. The top three positions are Seagen, Incyte Corporation, and BeiGene, and they add up to almost 68% of the portfolio. ...

P RESS RELEASE Immunocore announces the presentation of initial data from the P hase 1 ImmTAV ® trial for chronic Hepatitis B at the EASL International Liver Congress™ IMC- I109V , T cell recep...